What was the primary driver of Stryker's revenue growth in this period?

Stryker's revenue growth was driven by strong performance in both its Orthopaedic Implants and MedSurg Equipment segments. Increased unit volume and favorable changes in product mix, along with healthy international sales growth on a constant currency basis, contributed significantly to the top-line expansion.

Did Stryker experience any significant one-time charges or gains during this quarter?

Yes, Stryker recorded a $19.8 million ($12.7 million net of tax) intangible asset impairment charge in the Orthopaedic Implants segment related to patents for intervertebral body fusion cage products. Additionally, the company recognized a $25.7 million gain on the sale of its Physiotherapy Associates business.

How did the divestiture of Physiotherapy Associates impact the company's financial position?

The divestiture of Physiotherapy Associates provided $150 million in cash and resulted in a $25.7 million gain, strengthening the company's financial position. It also allowed Stryker to streamline its operations and focus more intently on its core medical technology business.

What is Stryker's outlook for the remainder of 2007?

Stryker has an optimistic outlook for 2007, projecting diluted earnings per share from continuing operations to approximate $2.37, representing a 27% increase over 2006. The company anticipates continued underlying growth in orthopaedic procedures and sales growth across its product lines.

SYK 10-Q Quarterly Report Q2 FY2007 — Revenue, Net Income, EPS

Summary

Stryker Corporation (SYK) reported strong financial results for the six months and second quarter ended June 30, 2007. Net sales saw significant year-over-year growth, driven by both its Orthopaedic Implants and MedSurg Equipment segments, with international sales also showing robust performance on a constant currency basis. The company successfully divested its outpatient physical therapy business, Physiotherapy Associates, realizing a substantial gain and allowing for increased focus on its core medical technology markets. Profitability also improved, with net earnings from continuing operations showing a significant increase compared to the prior year. This growth was supported by improved gross margins and disciplined expense management. The company provided an optimistic outlook for the remainder of 2007, projecting substantial earnings per share growth, supported by continued procedural growth in orthopaedics and sales expansion across its product portfolio. Investors should note a one-time intangible asset impairment charge impacting the second quarter results, which is detailed in the report.

Key Highlights

1Net sales increased by 15% to $2.9 billion for the six months ended June 30, 2007, and by 16% to $1.5 billion for the second quarter, with strong contributions from both Orthopaedic Implants and MedSurg Equipment segments.
2The company completed the sale of its Physiotherapy Associates business, realizing a gain of $25.7 million and allowing for greater strategic focus on medical technology.
3Net earnings from continuing operations grew by 35% to $481.9 million for the six months and by 13% to $240.1 million for the second quarter, demonstrating solid profitability improvement.
4Operating income increased by 25% for the first half of the year, reflecting improved gross profit and efficient management of operating expenses.
5The company divested its outpatient physical therapy business, Physiotherapy Associates, for $150 million, generating a gain of $25.7 million.
6Stryker provided an optimistic 2007 outlook, projecting diluted EPS from continuing operations of approximately $2.37, a 27% increase over 2006.
7An intangible asset impairment charge of $19.8 million was recorded in the second quarter related to intervertebral body fusion cage products.

STRYKER CORP Quarterly Report for Q2 Ended Jun 30, 2007

Summary

Key Highlights

Frequently Asked Questions